A Phase Ⅱ Study of Vinorelbine/Cisplatin with or without Cox-2 Inhibitor in First-Line Treatment of Non-small Cell Lung Cancer

Objective 　To investigate the efficacy and safety of vinorelbine/ cisplatin (NP) with COX22 in2 hibitor (celecoxib) in the first2line t reatment of non2small cell lung cancer (NSCLC) . Methods 　Sixty pa2 tient s with NSCLC were randomly assigned to receive NP regimen with or without celecoxib 400 mg twice daily, for 2 cycles at least, meanwhile the expression of COX22 receptor f rom their specimen were detec2 ted by IHC. Results 　Response rate (RR) were 43. 3 % for patient s t reated with celecoxib and 40 % for those t reated with chemotherapy alone, Median survival time (MST) were 9. 8 and 9. 5 months respec2 tively( P > 0. 05) . The main toxicities in the two arms were nausea and vomitting, myelosuppression, without any significant difference. Conclusion 　Compared with NP alone, celecoxib combined with NP was not able to improve efficacy or prolong survival, nor did it increase toxicities.